BR3006A
Sponsors
Boryung Pharmaceutical Co., Ltd
Conditions
Type 2 Diabetes
Phase 1
A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fed Conditions
CompletedNCT06890299
Start: 2024-12-05End: 2025-01-12Updated: 2025-03-24
A Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of BR3006 and Co-administration of BR3006A, BR3006B and BR3006C in Healthy Adult Volunteers Under Fasting Conditions
CompletedNCT06890286
Start: 2024-12-01End: 2025-01-03Updated: 2025-03-24